Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other EventsItem 8.01. Other Events.
On June5, 2018, Axsome Therapeutics,Inc. (the “Company”) issued a press release announcing the enrollment of the first patient into the Company’s Phase 2 ASCEND (Assessing Clinical Episodes in Depression) Study, a Phase 2 trial evaluating the efficacy and safety of AXS-05 in patients with Major Depressive Disorder.
The full text of the press release is filed as Exhibit99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
Description |
99.1 |
Press Release dated June5, 2018. |